RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study
- 1 September 2017
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 83, 185-193
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic FactorsJournal of Clinical Oncology, 2012
- An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New TherapeuticsClinical Cancer Research, 2010
- Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agentsAnnals of Oncology, 2009
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experienceAnnals of Oncology, 2008
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast CancerClinical Cancer Research, 2006
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECISTJournal of Clinical Oncology, 2004
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000